Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19

2020 ◽  
Author(s):  
Xiangyang Xie ◽  
Yuanliang Jiang ◽  
Yuan Zeng ◽  
Hui Liu
Keyword(s):  
Antiviral Therapy ◽  
Combination Antiviral Therapy

Combination Antiviral Therapy in Patients With Bell Palsy

2020 ◽  
Vol 146 (10) ◽  
pp. 977
Author(s):  
J. Alexander de Ru ◽  
Ahmed Bayoumy Bayoumy
Keyword(s):  
Antiviral Therapy ◽  
Combination Antiviral Therapy ◽  
Bell Palsy

scholarly journals Clinical Recommendations for the Use of Recombinant Human Erythropoietin in Patients with Hepatitis C Virus Being Treated with Ribavirin

2006 ◽  
Vol 20 (7) ◽  
pp. 479-485 ◽  
Author(s):  
Morris Sherman ◽  
Lawrence Cohen ◽  
Mary Anne Cooper ◽  
Magdy Elkashab ◽  
Victor Feinman ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Sustained Virological Response ◽  
Virological Response ◽  
Recombinant Human Erythropoietin ◽  
Pegylated Interferon ◽  
Pegylated Interferon Alpha ◽  
Human Erythropoietin ◽  
Combination Antiviral Therapy

Today, combination antiviral therapy with pegylated interferon-alpha and ribavirin (RBV) allows many patients infected with hepatitis C virus (HCV) to achieve a sustained virological response, which is equivalent to cure. Data also support the clinical benefit of combination antiviral therapy in patients coinfected with HCV and HIV, and in patients who have received a liver transplant.Antiviral therapy with pegylated interferon-alpha and RBV is, however, associated with a high incidence and significant magnitude of anemia. This anemia may have several mechanisms, including bone marrow suppression and hemolysis. In addition, patients coinfected with HIV may have both pre-existing and RBV-associated anemia. Management of anemia in patients with HCV through RBV dose reduction or treatment discontinuation may compromise the effectiveness of treatment, because studies have demonstrated that treatment adherence or maintenance of antiviral therapy dose is an important predictor of sustained virological response.Anemia associated with combination antiviral therapy in patients with HCV is frequently associated with an inadequate or blunted endogenous erythropoietin response. Accumulating evidence now supports the use of recombinant human erythropoietin (rHuEpo) to manage anemia in these patients, with the objective of maintaining the RBV dose, but clinical standards are lacking. The present article reviews the data relevant to the use of rHuEpo in this patient population and proposes a set of clinical practice standards to assist clinicians in selecting patients for rHuEpo and in implementing rHuEpo therapy effectively.

scholarly journals Absence of HIV-1 Evolution in the Gut-Associated Lymphoid Tissue from Patients on Combination Antiviral Therapy Initiated during Primary Infection

2012 ◽  
Vol 8 (2) ◽  
pp. e1002506 ◽  
Author(s):  
Teresa H. Evering ◽  
Saurabh Mehandru ◽  
Paul Racz ◽  
Klara Tenner-Racz ◽  
Michael A. Poles ◽  
...  
Keyword(s):  
Antiviral Therapy ◽  
Lymphoid Tissue ◽  
Primary Infection ◽  
Combination Antiviral Therapy ◽  
Hiv 1

Combination Antiviral Therapy in Patients With Bell Palsy—Reply

2020 ◽  
Vol 146 (10) ◽  
pp. 978
Author(s):  
Myung Chul Yoo ◽  
Sung Su Kim ◽  
Seung Geun Yeo
Keyword(s):  
Antiviral Therapy ◽  
Combination Antiviral Therapy ◽  
Bell Palsy

scholarly journals Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019

2020 ◽  
Vol 160 ◽  
pp. 105036 ◽  
Author(s):  
Xin Li ◽  
Yi Yang ◽  
Lancong Liu ◽  
Xuefeng Yang ◽  
Xiaobo Zhao ◽  
...  
Keyword(s):  
Antiviral Therapy ◽  
Combination Antiviral Therapy
Sign in / Sign up

Export Citation Format

Share Document